

Research progress concerning m⁶A methylation and cancer (Review)

YANG ZHOU, JIE YANG, ZHENG TIAN, JING ZENG and WEIGAN SHEN

Department of Cell Biology, School of Medicine of Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China

Received May 28, 2021; Accepted August 20, 2021

DOI: 10.3892/ol.2021.13036

Abstract. N6-methyladenosine (m⁶A) methylation is a type of methylation modification on RNA molecules, which was first discovered in 1974, and has become a hot topic in life science in recent years. m⁶A modification is an epigenetic regulation similar to DNA and histone modification and is dynamically reversible in mammalian cells. This chemical marker of RNA is produced by m⁶A ‘writers’ (methylase) and can be degraded by m⁶A ‘erasers’ (demethylase). Methylated reading protein is the ‘reader’, that can recognize the mRNA containing m⁶A and regulate the expression of downstream genes accordingly. m⁶A methylation is involved in all stages of the RNA life cycle, including RNA processing, nuclear export, translation and regulation of RNA degradation, indicating that m⁶A plays a crucial role in RNA metabolism. Recent studies have shown that m⁶A modification is a complicated regulatory network in different cell lines, tissues and spatio-temporal models, and m⁶A methylation is associated with the occurrence and development of tumors. The present review describes the regulatory mechanism and physiological functions of m⁶A methylation, and its research progress in several types of human tumor, to provide novel approaches for early diagnosis and targeted treatment of cancer.

Contents

1. Introduction
2. Composition and function of m⁶A modified enzyme
3. Detection methods of m⁶A methylation
4. Prediction methods of m⁶A methylation sites
5. Association between m⁶A modification and malignancies
6. Conclusions

1. Introduction

Cancer is a gene-related disease with heredity and can be caused by various physical, chemical or biological factors (1). It is usually characterized by abnormal differentiation and proliferation of cells, which differ from normal cell proliferation and apoptosis (2). In addition, tumor cells have invasive and metastasis abilities, and promote angiogenesis. N6-methyladenosine (m⁶A) methylation is an epigenetic modification of RNA, first discovered in the mRNA of eukaryotes in the 1970s (3). However, due to the limitation of technology, scientists hypothesized that the m⁶A methylation site only existed in mRNA. In recent years, m⁶A methylation has been found in different types of RNA, such as long non-coding RNA (lncRNA) (4), microRNA (5) and mRNA (6). With the rapid development of high-throughput sequencing technology, a variety of bioinformatics platforms, for predicting m⁶A methylation sites, have been developed, which increased the investigation of m⁶A methylation (7). In the process of carcinogenesis, m⁶A methylation has been associated with the occurrence and development of cancer by regulating the expression level of oncogenes and cancer suppressor genes. For example, in leukemia, METTL-14 causes the occurrence and development of leukemia via m⁶A RNA modification of *MYB/myc* (8). In liver cancer, METTL-3 promotes cancer progression through YTHDF2 dependent posttranscriptional silencing of *SOCS2* (9). Similar to DNA methylation, m⁶A methylation is regulated by methyltransferase and demethylase, which modulates post-transcriptional modifications without alternating the gene sequence (10). However, its regulatory mechanism is more complicated than DNA methylation. The present review explains the m⁶A-related enzymes, research methods and research progress of m⁶A methylation and cancer, and to describe the association between m⁶A methylation and tumor occurrence and development. An improved

Correspondence to: Professor Weigan Shen, Department of Cell Biology, School of Medicine of Yangzhou University, 136 Jiangyang Middle Road, Yangzhou, Jiangsu 225000, P.R. China
E-mail: shenweigan@hotmail.com

Abbreviations: m⁶A, N6-methyladenosine; FTO, fat mass and obesity-associated protein; ALKBH5, AlkB homologous protein 5; YTHDF2, YTH N6-methyladenosine RNA binding protein 2; eIFs, eukaryotic initiation factors; MeRIP-Seq, methylated RNA immunoprecipitation sequencing; miCLIP-seq, m⁶A individual nucleotide resolution cross-linking and immunoprecipitation; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; SAM, S-adenosylmethionine; PDAC, pancreatic ductal adenocarcinoma; CSCC, cervical squamous cell carcinoma; HIF, hypoxia-inducible factors; IGF2BP2, insulin like growth factor 2 mRNA binding protein 2; snRNA, small nuclear RNA; BCSCs, breast cancer stem cells; ZFP217, zinc-finger protein 217

Key words: RNA methylation, m⁶A methylation, tumor

understanding of m⁶A methylation could assist with identifying potential biomarkers and targets for molecular diagnosis and targeted therapy of cancer.

2. Composition and function of m⁶A modified enzyme

m⁶A is a dynamic and reversible modification process, which mainly involves three types of catalytic enzymes: Methyltransferase, demethylase and methylated reading protein (Table I). Methyltransferase, also known as mRNA 'writer', methylates adenosine in mRNA (11). *METTL-14* and *METTL-3* can form a methyltransferase complex by binding to the regulatory protein, WT1 associated protein (*WTAP*) and subsequently promote methylation. m⁶A modified mRNA specifically binds to methylated reading protein, termed as 'reader', and results in various effects on gene expression (12). Demethylase (mRNA erasers) can remove the methyl group on adenosine bases for m⁶A demethylation. The mRNA writers and erasers make m⁶A modification a dynamic and reversible process. Previous studies hypothesized that m⁶A modification could change the secondary structure of RNA, promote the combination of RNA binding protein with RNA segments, interfere with RNA modification and subsequently regulate gene expression (13,14). However, the underlying mechanism remains unclear.

mRNA writers. m⁶A methylation is catalyzed by mRNA writers, including *METTL-3*, *METTL-14*, *WTAP*, *VIRMA* and *RBM15*. The core components of the m⁶A methyltransferase complex (*METTL-3*, *METTL-14*, *WTAP* and *VIR*) are highly conserved in most eukaryotes (15). The study of the m⁶A site on human small nuclear (sn) RNA U6 showed that human cells express at least one activated m⁶A methyltransferase, apart from *METTL-14* and *METTL-3*. However, these enzymes have not been identified due to the limitation in technology.

***METTL-3*.** *METTL-3*, also known as MT-A70, is the earliest reported m⁶A methylase. Barbieri *et al* (16) reported that the upregulation of *METTL-3* expression significantly promoted the m⁶A methylation of mRNA transcribed by the oncogene *SPI*, resulting in an increased expression of the *SPI* protein, which was associated with the differentiation of hematopoietic stem cells into acute myeloid leukemia (AML) cells. In addition, Vu *et al* (17) confirmed that downregulation of *METTL-3* gene expression increased the phosphorylation of *AKT* and promoted the differentiation of hematopoietic stem cells into AML cells. The two studies provide novel directions for the diagnosis and treatment of AML.

In addition, some studies have shown that under hypoxia, the transcription factor zinc-finger protein 217 (*ZNF217*) inhibited the m⁶A modification of *KLF4* and *NANOG* by binding to *METTL-3*, leading to elevated expression of *KLF4* and *NANOG*, and the promotion of breast cancer (18). Cai *et al* (19) have found that high expression of *METTL-3* in breast cancer cells induced m⁶A modification on *HBXIP* mRNA. *HBXIP* promoted the m⁶A modification of *METTL-3* by reducing the expression level of tumor suppressor gene *LET-7G*, which forms a positive feedback pathway with *HBXIP/LET-7G/METTL-3/HBXIP* and promoted the malignant biological behaviors of breast cancer. These studies

provide new approaches for the diagnosis and treatment of breast cancer.

Furthermore, Chen *et al* (9) found that overexpressed *METTL-3* in primary hepatocellular carcinoma (HCC) could change the m⁶A modification of the tumor suppressor gene, *SOCS2*, leading to degradation of *SOCS2* mRNA and promotion of cancer cell proliferation and migration. This study showed that hypermethylation was associated with the progression of HCC. Taketo *et al* (20) found that, in pancreatic cancer cell lines with low expression of *METTL-3*, the cancer cells were more sensitive to gemcitabine and other anticancer drugs [Everolimus (21) or Elemsene (22)] and external radiation. In addition, *METTL-3* was associated with cell cycle regulation, mitogen-activated protein kinase cascade and RNA splicing, suggesting that *METTL-3* may be one of the potential targets to improve the therapeutic efficacy in patients with pancreatic cancer.

However, in renal cell carcinoma (RCC), *METTL-3* exhibited tumor-suppressing activity (23). *In vivo* experiments confirmed that lower expression of *METTL-3* was significantly associated with tumor histological grade and tumor size. In addition, patients with RCC and overexpression of *METTL-3* had a higher overall survival rate and good prognosis. Downregulation of the *METTL-3* gene expression in a RCC cell line could promote cell epithelial-mesenchymal transition (EMT), proliferation, invasion and metastasis. It was suggested that *METTL-3* could be used as a new marker for the treatment of RCC, however, further studies are required to investigate the role of *METTL-3* and related factors in carcinogenesis to further understand the biological mechanism of the occurrence and development of RCC.

The aforementioned studies have investigated the different activities of *METTL-3* in various types of cancer, indicating that m⁶A methyltransferase, *METTL-3* could be a potential target for developing novel therapeutic strategies, and investigating the mechanism of the occurrence and development of cancer.

***METTL-14*.** *METTL-14* is a homologous heterodimer of *METTL-3* in the MT-A70 methyltransferase family (24). It has been reported that knockout of the *METTL-14* gene in HeLa cells led to a decrease in m⁶A methylation level, suggesting that *METTL-14* was an important part of the m⁶A methyltransferase complex (25). Since *METTL-3* is a subunit with catalytic activity, *METTL-14* is responsible for identifying substrates. The two proteins are combined to form a stable methyltransferase complex with a ratio of 1:1 *In vivo*, which allows the catalyzation of m⁶A modification in target RNA (26). Weng *et al* (8) found that the knockout of *METTL-14* in AML cell lines could effectively inhibit the proliferation of the AML cells. *METTL-14* was negatively regulated by *SPI* at the protein level and induced cancer promotion by regulating target genes via m⁶A modification. This study firstly revealed the role of the *SPI-METTL-14-MYB/MYC* signal axis in the progression, maintenance, and self-renewal of leukemia, providing new ideas for the diagnosis and treatment of AML. In addition, Ma *et al* (27) proved that the decrease in expression of *METTL-14* in HCC tissue was an independent factor in predicting cancer recurrence. The reduction of *METTL-14* led to a decreased level of m⁶A methylation, which inhibited

Table I. m⁶A modification-related enzymes and their biological functions in tumors.

Type	Gene	Function
Writer	METTL-3	Methyltransferase
	METTL-14	Enhancing radiotherapy and chemosensitivity
	METTL-16	Enhancing mRNA initiation translation
	WTAP	Plays a role in both transcriptional and post-transcriptional regulation of certain cellular genes
Eraser	WTAP	Demethylase, downregulating mRNA transcription levels.
	ALKBH5	Promoting chemotherapy resistance Mediating m ⁶ A demethylation modification, maintaining tumorigenicity of tumor cells and pre-mRNA stability
Reader	YTHDF1/2	Recognition and binding of m ⁶ A sites selectively and mediating mRNA degradation
	eIF3	Promoting translation independent of 5'-UTR under stress conditions

eIF3, eukaryotic initiation factors; UTR, untranslated region; YTHDF2, YTH N6-methyladenosine RNA binding protein 2; ALKBH5, AlkB homologous protein 5; WTAP, WT1 associated protein; m⁶A, N6-methyladenosine.

cell proliferation and promoted apoptosis of HCC cells. In a HCC cell line, *METTL-14* mediated the decreased expression of miR-126, leading to the invasion and metastasis of HCC. Furthermore, Ma *et al* also found that the expression level of *METTL-14* and demethylase *WTAP* in HCC was decreased, indicating that m⁶A modification has a complicated feedback regulation mechanism. Therefore, the investigation into the interaction between *METTL-14* and micro (mi) RNA could provide novel targets for the treatment of HCC.

METTL-16. *METTL-16* is a newly discovered m⁶A methyltransferase (28). The downregulated expression of *METTL-16* led to a decrease in the level of m⁶A methylation in cells. Warda *et al* (29) found that *METTL-16* could bind to snRNA U6, long non-coding (lnc) RNA and pre-mRNA via cDNA cross-linking analysis, which deepened the understanding of the interaction between m⁶A and other RNA.

S-adenosylmethionine (SAM) is an important methyl donor of DNA methylation and acts as a key regulator controlling gene expression (30). It has previously been reported that SAM played an important role in RNA methylation (31). The study suggested that *METTL-16* maintained the stability of intracellular SAM by regulating the alternative splicing of *MAT2A*. The absence of SAM increased the residence time of *METTL-16* in the hairpin of *MAT2A* 3' untranslated region (UTR) and promoted the alternative splicing of *MAT2A*, subsequently regulating the homeostasis of intracellular SAM content (32). The association between RNA modification and alternative splicing was established by this mechanism. However, the association between *METTL-16* and the occurrence and development of cancer remains unclear. Therefore, further studies are required to investigate the role of *METTL-16* in cancer development.

WTAP. *WTAP* is an essential component in m⁶A methylation modification. Ping *et al* (33) proved that *WTAP* assisted

with the accurate location of the *METTL-3-METTL-14* heterodimer and promoted m⁶A methylation. In addition, either knockdown or overexpression of *METTL-3* led to an elevation of *WTAP* expression, indicating that *METTL-3* plays an important role in the regulation of *WTAP* function (34). However, the upregulation of *WTAP* could not promote cancer cell proliferation in the absence of *METTL-3*. Therefore, the carcinogenic effect of *WTAP* is associated with the m⁶A methyltransferase complex. The association between *WTAP* and the occurrence and development of cancer is unclear. Xi *et al* (35) found that *WTAP* was highly expressed in glioma tissue and was associated with pathological grade and poor postoperative survival rate. Li *et al* (36) confirmed that the expression level of *WTAP* was significantly increased in both the cytoplasm and nucleus of pancreatic ductal adenocarcinoma (PDAC), whereas the high expression level in the nucleus was significantly associated with sex and tumor stage and was considered to be an independent prognostic factor of PDAC. Tang *et al* (37) reported that the high expression level of *WTAP* in patients with RCC was associated with poor overall survival rate and prognosis. The study also found that *WTAP* may promote the proliferation of RCC cells by regulating the stability of *CDK2* mRNA, leading to the occurrence and development of cancer. Therefore, *WTAP* may become a new target for the diagnosis and treatment of RCC.

mRNA erasers. α -ketoglutarate-dependent dioxygenase FTO protein (*FTO*) encoded by the obesity gene, FTO was the first demethylase found in mammals, which proved that m⁶A modification was dynamically reversible (38). Similarly, AlkB homologous protein 5 (*ALKBH5*) in mammals could also catalyze the restoration of m⁶A methylation (39). Currently, it is not clear whether demethylases exist in lower-grade eukaryotes. Some studies have found that when the first nucleotide adjacent to the cap in the nucleotide sequence is adenosine,

FTO cannot induce demethylation, but the specific mechanism is unclear.

***FTO*.** The *FTO* gene is located on chromosome 16 (16q12.2) and is widely expressed in all stages of human growth (40). Its main functions are to regulate the rate of fat consumption, promote the overall metabolic rate, and ensure the energy balance of the body (41). Jia *et al* (42) first confirmed that the *FTO* protein was a crucial demethylase in both DNA and RNA modification, especially in m⁶A demethylation. This report ushered in the era of m⁶A research. Selberg *et al* (26) confirmed that the level of m⁶A in mRNA was increased in *FTO* knockout leukemia cells or gastric cancer cells and vice versa. However, the expression of m⁶A methylase *METTL-3* was not affected. Based on these results, researchers preliminarily proved that the methylation process of m⁶A was reversibly and dynamically regulated. Previous studies have shown that the expression of the *FTO* gene was associated with breast cancer (41), thyroid cancer (43), endometrial cancer (44), gastric cancer (45), and other types of cancer (46,47). Li *et al* (48) found that *FTO* increased leukemia oncogene-mediated cell transformation and leukemogenesis by reducing the m⁶A modification of *ASB2* and *RARA* genes, which led to the inhibition of AML cell differentiation induced by all-trans retinoic acid. In another study, Zhou *et al* (49) found that the expression of the *FTO* gene was significantly increased in patients with cervical squamous cell carcinoma (CSCC), and the increased expression of *FTO* and β -catenin indicated a poor prognosis. Therefore, the expression level of *FTO* and β -catenin could predict the prognosis of CSCC. In short, few studies have focused on the mechanism of *FTO*-induced m⁶A modification in the carcinogenesis and development of cancer. More studies are required to clarify the relevant molecular biological mechanisms involved in *FTO*-induced m⁶A modification. However, it remains controversial whether the activity of methylase and demethylase is limited to catalyzing m⁶A modification on RNA.

***ALKBH5*.** *ALKBH5* belongs to the AIkB family, but unlike other family members, *ALKBH5* only has demethylation ability on single-stranded RNA/DNA (50). With the participation of hypoxia-inducible factors (HIF), *ALKBH5* can induce the transformation of breast cancer cells into tumor stem cells by reducing the m⁶A methylation of *NANOG*, which improves the stability of *NANOG* mRNA and elevates its expression (51). Similarly, Zhang *et al* (52) found that *ALKBH5* was significantly overexpressed in glial stem cell-like cells (GSCs) and the interference of *ALKBH5* could inhibit the proliferation of GSCs. In addition, the study also found that lncRNA *FOXMI*-AS promoted the interaction between *ALKBH5* and *FOXMI*, indicating that m⁶A demethylase *ALKBH5* acted as an oncogene in glioma. Recently, low expression of *ALKBH5* in pancreatic cancer cell lines was found to promote the m⁶A demethylation of lncRNA *KCNK15*-AS1, resulting in a decreased ability of cancer invasion and metastasis (53). This provided a new direction for the diagnosis and treatment of pancreatic cancer.

In summary, further studies are required to investigate whether *ALKBH5* is associated with the occurrence and

development of other types of cancer and whether these key demethylation modifications are associated with the stability, translation, and alternative splicing of mRNA.

***mRNA readers*.** The term, mRNA readers, refers to proteins that can specifically bind to mRNA with m⁶A methylation. The YTH domain is the marker of m⁶A binding protein on mRNA. Their affinity with m⁶A methylated mRNA is higher than that of unmethylated mRNA (54). The carboxyl terminal domain of YTH N6-methyladenosine RNA binding protein 2 (*YTHDF2*) selectively binds to the m⁶A modified mRNA, which assists the *YTHDF2*-mRNA complex to move to the RNA decay site of the cell, thus inducing the degradation of mRNA. The degradation of mRNA plays an important role in stem cell differentiation by regulating key pluripotent factors (55). In different situations, the YTH protein can interact with different subsets of the m⁶A locus and induce different effects on gene expression. Insulin like growth factor 2 mRNA binding protein 2 (*IGF2BP2*) is another m⁶A reader using the Khomlog (KH) domain to selectively bind m⁶A modified RNA and promote mRNA translation, which is different from proteins with the YTH domain (56). This discovery increased the understanding of the mechanism and function of the m⁶A binding protein. In addition, m⁶A modification could destroy the complementary pairing of nucleotides, improve the accessibility of single-stranded RNA motifs, and promote the recognition of m⁶A binding proteins heterogeneous nuclear ribonucleoprotein C and G.

***YTH domain*.** The YTH domain recognizes m⁶A methylation in a methylation-dependent manner (57). A total of five proteins in the human body contain YTH domains. *YTHDC1* can regulate the expression of mRNA in the nucleus by affecting the alternative splicing of mRNA precursors (58). Zhao *et al* (35) found that the expression of *YTHDF1* was significantly increased in patients with advanced HCC. In addition, potential target genes regulated by the *YTHDF1* protein may be associated with the cell cycle of the tumor, degradation of different amino acids and metabolism of various lipids. Li *et al* (59) reported that overexpression of miR-493-3p in *YTHDF2* knockdown prostate cancer cell lines promoted m⁶A modification and thereby inhibited the proliferation and migration of the cancer cells. These findings lay a foundation for further investigation of the biological function of m⁶A and RNA epigenetics and provide a new direction for investigating the underlying mechanism of cancer development. Currently, the role of YTH family members in m⁶A methylation has become a hot topic, which provides novel approaches for investigating cancer-related mechanisms.

Eukaryotic initiation factors (*eIF3*). There are numerous and complex *eIFs*. Up to now, a total of 13 *eIFs* have been identified (60). *eIF3* is the most complex factor in *eIF* translation and plays an important role in the initiation of protein translation. Li *et al* (61) first found that *eIF3e* was an independent prognostic factor for overall survival and disease-free survival time in patients with colon cancer. Downregulation of *eIF3e* expression could inhibit proliferation and promote apoptosis of colon cancer cells. Furthermore, the interaction between *METTL-3* and *eIF3h* could increase mRNA translation and form dense polyribosomes, which was necessary for

Table II. Methods to detect and predict m⁶A methylation.

Method	Application	Characteristic
m ⁶ A-Seq	The region of m ⁶ A hypermethylation was identified, but the resolution of single base could not be achieved	High-throughput
MeRIP-Seq	The RNA fragments containing m ⁶ A were enriched with m ⁶ A antibody, and then the enriched fragments were sequenced	High-throughput
miCLIP-Seq	M ⁶ A antibody was used to enrich m ⁶ A modification, combined with UV crosslinking technology to identify m ⁶ A modification at single base level in the whole genome	High-throughput unit point
m ⁶ A-CLIP	M ⁶ A antibody was used to enrich m ⁶ A modification, combined with UV crosslinking technology to identify m ⁶ A modification at single base level in the whole genome	High-throughput unit point
PA-m ⁶ A-Seq	M ⁶ A antibody was used to enrich m ⁶ A modification, combined with UV crosslinking technology to identify m ⁶ A modification at single base level in the whole genome	High-throughput unit point

m⁶A, N6-methyladenosine; seq, sequencing; MeRIP, methylated RNA immunoprecipitation sequencing; miCLIP, m⁶A individual-nucleotide-resolution cross-linking and immunoprecipitation; PA, photo-cross-linking.

carcinogenic transformation (62). The study by Chao *et al* (39) revealed the regulatory mechanism of protein translation based on the mRNA cycle and indicated that *METTL-3-eIF3h* could be a potential therapeutic target for patients with lung cancer.

3. Detection methods of m⁶A methylation

In the early days, due to the limitation of technology, researchers could not detect m⁶A methylation sites. As m⁶A methylation of RNA does not affect its reverse transcription and it cannot be specifically cleaved, like M7G methylation, it is very difficult to identify the m⁶A site in the initial study (63). However, with the emergence of second-generation sequencing (seq), two techniques, screening m⁶A methylation site-m⁶A-seq (64) and methylated RNA immunoprecipitation sequencing (MeRIP-seq) have been developed (65). These methods were designed to capture RNA fragments with m⁶A methylation using co-immunoprecipitation then identify the sequences by second-generation sequencing. Subsequently, a multitude of m⁶A methylation sites were found, and researchers found up to 12,000 m⁶A signal peaks in >7,000 genes in humans and mice, all of which were enriched near the stop codon at the 3' end (66). These sites were highly conserved in both humans and mice. This finding provided strong evidence for the post-transcriptional regulation of m⁶A methylation for gene expression and the modification may be associated with various genetic diseases (67,68). A limitation of this technique is that the RNA fragments captured are limited to 100-200 nucleotides and the technique cannot identify two very-close m⁶A sites, so this method cannot accurately identify the m⁶A methylation sites in the full transcriptome (69). In addition, a novel m⁶A modification was found at the 5' end of mRNA (70). As m⁶A modification has the same methyl site with m⁶A modification, both m⁶A-seq and MeRIP-seq may misinterpret this modification as m⁶A modification.

Based on the aforementioned limitations, the detection technology was improved by researchers. In 2015, three laboratories reported that the application of purple diplomatic co-immunoprecipitation could accurately capture m⁶A methylation sites on a single base of RNA, which is the core technology of m⁶A individual-nucleotide-resolution cross-linking and immunoprecipitation (miCLIP) (69), photo-cross-linking-m⁶A-seq (71), and m⁶A-CLIP (or UV-CLIP) (72). Another technique for detecting m⁶A methylation site is m⁶A-LAIC-seq, which introduces spike-in-RNAs as an internal reference on the basis of m⁶A-seq to calculate the m⁶A methylation level of each gene in the full transcriptome (73). The disadvantage of this method is that a single m⁶A methylation site cannot be detected. In addition to Qualcomm sequencing, the methods detecting the m⁶A methylation site of a single gene are also important. The most famous one is site-specific cleavage and radioactive-labeling followed by ligation-assisted extraction and thin-layer chromatography (SCARLET) test (74), which can accurately detect a single m⁶A methylation site in mRNA and lncRNA, and calculate the m⁶A methylation level of the whole RNA (73). SCARLET is a low-throughput test with high expenses; however, its high accuracy makes it a common method for testing the accuracy of high-throughput detection of m⁶A methylation sites. In addition, SCARLET can be used to detect other types of epigenetic modifications of RNA, such as M5C modification and ψ modification (75). Fluorescence quantitative PCR can also be used to detect the level of m⁶A methylation. Golovina *et al* (76) found that different m⁶A methylation levels in the same RNA will produce different melting curves under fluorescence quantitative PCR detection, which is due to the different melting temperatures of the RNA-DNA complex with different m⁶A methylation levels. Therefore, Golovina *et al* proposed a high-resolution melting detection method, which could detect the alternation of the known m⁶A methylation level in RNA. However, the experiments were only performed with ribosomal RNA, total RNA and snRNA,

so whether this technology can be extended to other types of RNA remains to be verified.

With the progress of high-throughput sequencing and antibody-specific enrichment technology, a new detection method, methylated RNA immunoprecipitation sequencing (MeRIP-seq), was developed with the advantage of identifying almost all m⁶A modifications in different types of RNA, such as mRNA (77), lncRNA (78) and circular RNA (79). In MeRIP-seq, specific antibody of m⁶A is used to extract co-immunoprecipitated RNA fragments, which are further identified using high-throughput sequencing (80). Then, the m⁶A modification can be systematically investigated in combination with bioinformatics analysis. However, the main limitation of MeRIP-seq is that MeRIP-seq can only identify hypermethylated regions of the RNA, but cannot locate a certain m⁶A site (81).

Subsequently, a novel sequencing method, miCLIP-seq, was developed to identify the specific site of m⁶A modification. Apart from the application of m⁶A antibodies to identify and enrich m⁶A modification, miCLIP-seq also uses UV cross-linking method to identify m⁶A modification at the single-base level in the whole genome. Therefore, miCLIP-seq can efficiently detect the m⁶A residue with high resolution and perform m⁶A cluster analysis on the whole RNA, which provides a novel technique to investigate the unique epigenetic trait of RNA. Furthermore, miCLIP can also detect the m⁶A modification in a class of small non-coding RNA, such as small nucleolus RNA, which cannot be obtained using previous techniques. High-throughput sequencing technology has improved and is effective, but fluorescence quantitative detection is still one of the most economical and convenient molecular detection methods. There is clear importance to develop fluorescence quantitative PCR for m⁶A detection. With the gradual improvement of the detection methods of m⁶A methylation sites, a deeper understanding of m⁶A methylation will develop, which lays a solid foundation for the study into the association between m⁶A methylation and various diseases, particularly cancer. Table II lists the characteristics of five detection methods.

4. Prediction methods of m⁶A methylation sites

As the detection of the m⁶A methylation site is expensive and time consuming, bioinformatics prediction has been used to improve the research efficiency with high cost-effectiveness. In recent years, bioinformatics has developed rapidly and been widely used in molecular biology research. The following methods can assist with the prediction of the methylation sites of m⁶A more effectively. Yu-Chen *et al* (82) first proposed the use of the Hidden Markov Model (HMM) to predict the residual sites around known sites. Li *et al* (83) developed the pRNA-PC method to predict loci faster and was more stable. In addition, Chen *et al* (84) developed the iRNA-Methyl method. Based on these, Jia *et al* (85) developed the RNA-methylPred method, which is more stable and efficient than the former. After that, Li *et al* (83) proposed an improved Target m⁶A method, but this method could only predict the methylation site of m⁶A in the primary RNA sequence. On the other hand, Zhou *et al* (86) synthesized several mathematical models and proposed the sequence-based RNA adenosine methylation site predictor

(SRAMP) method, which could effectively predict m⁶A methylation sites in mammalian RNA. Recently, an online database called, RMBase-V2.0, has been established (<http://rna.sysu.edu.cn/rmbase/>), which contains a number of RNA epigenetic modification sequence data of 13 species, including a high amount of data on m⁶A methylation sites.

5. Association between m⁶A modification and malignancies

m⁶A modification and breast cancer. Breast cancer stem cells (BCSCs) can proliferate indefinitely via self-renewal and forming recurrent or metastatic tumors (87). In the hypoxic tumor microenvironment, *ALKBH5* could reduce m⁶A methylation in *NANOG* mRNA, increase the expression of *NANOG* mRNA and mediate the enrichment of BCSCs in a HIF-dependent manner (51). Zinc-finger protein 217 (*ZFP217*) and *ALKBH5* play complementary roles in regulating m⁶A methylation in RNA (18). Hypoxia-induced *ZNF217* inhibited m⁶A methylation of *NANOG* mRNA, whereas *ALKBH5* induced m⁶A demethylation. Taken together, they can increase the expression of *NANOG* mRNA and protein and enrich BCSCs. In addition, *ZFP217* and *ALKBH5* were associated with a more malignant phenotype of breast cancer by inhibiting m⁶A methyltransferase-related modifiers or inducing HIF-dependent hypoxia (88). A recent study reported that m⁶A modification regulated the expression of early polyadenylation (premature polyadenylation; PPA), which blocked the expression of tumor suppressor genes and lead to carcinogenesis (89). In breast cancer cells, premature polyadenylation causes oncogenic truncations of the tumor suppressor genes *MAGI3* (90), *LATS1* (91) and *BRCA1* (92). The activation and truncation of PPA in tumor suppressor genes was regulated by m⁶A modification. Compared with that in normal breast cells, m⁶A methylation, activated by PPA significantly, was decreased in tumor suppressor gene-related exons. However, there are no conclusions on how breast cancer cells regulate the level of m⁶A in exons to trigger PPA.

m⁶A modification and colon cancer. As an ATP-dependent RNA helicase and a member of the YTH family, *YTHDF2* promoted initial translation by unlocking the 5'-UTR of mRNA, and the transcription and translation of metastasis-related factors by inducing m⁶A methylation, thereby enhancing the metastasis of cancer cells (93). In colon cancer, *YTHDF2* promoted metastasis by promoting the translation of HIF-1 α . Knockdown of the *YTHDF2* gene could reduce the expression level of metastasis-related genes, such as HIF-1 α and inhibit the metastasis of colon cancer cells *in vitro* and *In vivo* (94). In addition, the expression level of *YTHDF2* was positively associated with the stage of colon cancer. At present, few studies have identified the function and target of *YTHDF2* in the progression and metastasis of colon cancer. However, these findings will provide new insights into the role of RNA demethylase in tumorigenesis.

m⁶A modification and liver cancer. Hou *et al* (95) have revealed that *YTHDF2* was positively associated with the malignant grade of HCC. miR-145 could increase the level of m⁶A methylation by targeting the 3'-UTR of *YTHDF2* mRNA in HCC cells, leading to the malignant progression of HCC.

In addition, *YTHDF1* was highly expressed in human HCC tissues and associated with the regulation of the cell cycle and metabolism of HCC cells. Furthermore, the deletion of m⁶A methylation was associated with the metastasis of HCC with the downregulation of *METTL-14*. In HCC, *METTL-3* mediated the methylation of m⁶A in the mRNA of the chromosome (or critical) region in DiGeorge syndrome (96). *METTL-14* could significantly upregulate the level of miR-126 modified by m⁶A methylation, thus promoting the maturation of miR-126 and inhibiting the metastasis of HCC cells (97). At present, the mechanism of how *METTL-14* has a low expression in liver cancer cells remains unclear. More in-depth investigation is required to clarify the structure and biological function of *METTL-14* in cancer to determine whether *METTL-14* can be used as a therapeutic target for the treatment of liver cancer. However, the interaction between *METTL-14* and *YTHDF1/2* with miRNA still provides clues for identifying new approaches to treat liver cancer.

m⁶A modification and pancreatic cancer. The role of *METTL-14* in pancreatic cancer has also been confirmed. The methylase, *METTL-14* was highly expressed in pancreatic cancer tissues. *METTL-14* could promote the proliferation, invasion, and metastasis of pancreatic cancer cells by increasing the level of m⁶A methylation, inhibiting the expression of miR-1-3p, and activating the mitogen-activated protein kinase (MAPK) pathway (98). In addition, a new mechanism of lncRNA with m⁶A methylation was found. *ALKBH5* inhibited the progression of pancreatic cancer by promoting m⁶A demethylation of lncRNA potassium two-pore domain channel subfamily K member 15 (*KCNK15*) and WNT1-induced signal pathway protein 2 (*WISP2*) antisense lncCNK15-AS1 (53). This finding reveals a new area for investigating the role of lncRNA methylation in cancer development.

m⁶A modification and hematopoietic tumor. *WTAP*, as an m⁶A demethylase, plays a carcinogenic role in AML. Both *in vivo* and *in vitro* research has proved that *WTAP* was associated with cell transformation and all-trans retinoic acid (ATRA)-mediated leukemia cell differentiation (48). In addition, *METTL-3* inhibited the differentiation of hematopoietic stem/progenitor cell in patients with AML by inducing m⁶A methylation, which maintained the undifferentiated phenotype of the leukemia cells and promoted the occurrence of AML. On the other hand, the knockdown or deletion of *METTL-3* could activate a translation process to promote cell differentiation and apoptosis, leading to the suppression of leukemia cells without affecting normal hematopoietic cells (17). Similarly, *METTL-14* plays a key role in both normal myelopoiesis and pathogenesis of AML (8). *METTL-14* could block normal myeloid differentiation and promote malignant bone marrow formation by mediating m⁶A methylation. These studies provide new insights into the molecular mechanism of hematological tumorigenesis, suggesting that inhibition of *METTL-3/14* may be used as a strategy for the treatment of malignant myeloid tumors.

m⁶A modification and endometrial carcinoma. In 2018, a study found that m⁶A methylation in mRNA played a crucial role in endometrial carcinogenesis with the activation of

protein kinase B (PKB) signal (99). m⁶A methylation reduced the expression of PKB negative regulator PH domain and leucine-rich repetitive protein phosphatase 2, whereas the expression of the positive PKB regulator mammalian target of rapamycin c2 was elevated, which promoted the proliferation and invasion endometrial cancer cells (49).

m⁶A modification and cervical cancer. Previous studies have found that a low level of m⁶A was associated with the occurrence of cervical cancer. In addition, the decrease in m⁶A level was positively associated with The International Federation of Gynecology and Obstetrics stage, tumor size, degree of differentiation, lymph node invasion and tumor recurrence (100). The results suggested that m⁶A methylation site in mRNA may serve as a potential therapeutic target for cervical cancer and could be used as an independent prognostic factor for predicting disease-free survival and overall survival times in patients with cervical cancer (101,102).

m⁶A modification and gastric cancer. In gastric cancer, the expression level of *ALKBH5*, a m⁶A 'eraser', was significantly decreased in highly invasive diffuse gastric adenocarcinoma compared with that in adjacent tissues. The knockdown of *ALKBH5* could decrease the mRNA and protein expression levels of E-cadherin and increase the expression level of interstitial markers, such as snail (103) and N-cadherin (104). Further investigation showed that the downregulation of *ALKBH5* could decrease the ability of mRNA demethylation and promote the methylation level, which reduced the stability of E-cadherin mRNA and promoted the invasion of tumor cells. Furthermore, *ALKBH5*, as a tumor suppressor gene in gastric cancer (105), could suppress EMT, migration, and invasion of gastric cancer cells by inhibiting the mRNA and protein expression levels of *MMP-2* and *MMP-9*. In addition, *WTAP* was found to play an important role in the progression and metastasis of gastric cancer, and was associated with poor differentiation, lymph node metastasis, high TNM stages and poor prognosis (106). M⁶A may also be an important molecular marker for monitoring gastric cancer. Furthermore, the expression level of *METTL-3* was positively associated with the prognosis, tumor grade and tumor stage in patients with gastric cancer (107). In addition, *METTL-3* was associated with the mRNA and protein expression levels of α -smooth muscle actin to regulate the proliferation and migration of gastric cancer cells, which could be a potential target for the treatment of gastric cancer in the future (108,109).

m⁶A modification and other types of cancer. They regulate the level of m⁶A through direct or indirect modification and participate in tumor progression. *WTAP* enhanced the expression of marrow zinc finger 1 (*MZF1*) by reducing the level of m⁶A and destabilizing *MZF1* mRNA in bone, thus promoting the progression of lung squamous cell carcinoma. *YTHDF2* and miR-495 inhibited the progression of prostate cancer by indirectly downregulating the level of m⁶A methylation (110). *ALKBH5* maintained the expression level of fork box protein M1 mRNA by promoting m⁶A demethylation, which retained the tumorigenicity of glioblastoma stem cells (52). The aforementioned studies revealed the importance of m⁶A

modification in different types of cancer. The dynamic change of m⁶A methylation has various regulatory effects on cancer cells (111). By revealing the previously unidentified regulation mechanism in tumors, further studies will provide bases for exploring the pathogenesis of tumors and developing new potential targets for cancer treatment (112,113).

6. Conclusions

Since m⁶A methylation plays an important role in numerous types of malignant tumor, m⁶A modification could be used as a diagnostic/prognostic target. Due to the effect of various related factors, the results of from several researchers are sometimes contradictory. This requires more multicenter and large-scale research for further investigation, thus laying the foundation for accurate treatment of human tumors.

Acknowledgements

The authors would like to thank Mrs. Wei Zhou and Mrs. Keyan Wu (Department of Cell Biology, School of Medicine of Yangzhou University) for their help with the literature search.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Author's contributions

YZ conceived and designed this study. The literature search was carried out by JY. ZT and JZ were involved in drafting the manuscript or revising it critically for important intellectual content, in addition they resolved any disagreements. The manuscript was drafted by YZ and WS. Manuscript revisions and modifications were carried out by YZ. Final changes were made by JY and WS. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for participation

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, *et al*: Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. *Eur Urol* 77: 320-330, 2020.
2. Enane FO, Sauntharajah Y and Korc M: Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. *Cell Death Dis* 9: 912, 2018.
3. Li J, Yang X, Qi Z, Sang Y, Liu Y, Xu B, Liu W, Xu Z and Deng Y: The role of mRNA m⁶A methylation in the nervous system. *Cell Biosci* 9: 66, 2019.
4. Lv Z, Sun L, Xu Q, Xing C and Yuan Y: Joint analysis of lncRNA m⁶A methylome and lncRNA/mRNA expression profiles in gastric cancer. *Cancer Cell Int* 20: 464, 2020.
5. Pan X, Hong X, Li S, Meng P and Xiao F: METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m⁶A-dependent manner. *Exp Mol Med* 53: 91-102, 2021.
6. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y, *et al*: m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. *Nature* 548: 338-342, 2017.
7. Liu K and Chen W: iMRM: A platform for simultaneously identifying multiple kinds of RNA modifications. *Bioinformatics* 36: 3336-3342, 2020.
8. Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, *et al*: METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification. *Cell Stem Cell* 22: 191-205.e9, 2018.
9. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, *et al*: RNA N⁶-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. *Hepatology* 67: 2254-2270, 2018.
10. Chen J, Zhang YC, Huang C, Shen H, Sun B, Cheng X, Zhang YJ, Yang YG, Shu Q, Yang Y and Li X: m⁶A regulates neurogenesis and neuronal development by modulating histone methyltransferase Ezh2. *Genomics Proteomics Bioinformatics* 17: 154-168, 2019.
11. Lin S, Choe J, Du P, Triboulet R and Gregory RI: The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. *Mol Cell* 62: 335-345, 2016.
12. Shi H, Wei J and He C: Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. *Mol Cell* 74: 640-650, 2019.
13. Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L and Pan T: N⁶-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. *Nucleic Acids Res* 45: 6051-6063, 2017.
14. Liu N, Dai Q, Zheng G, He C, Parisien M and Pan T: N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. *Nature* 518: 560-564, 2015.
15. Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S and Liu T: The critical role of RNA m⁶A methylation in cancer. *Cancer Res* 79: 1285-1292, 2019.
16. Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, *et al*: Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation control. *Nature* 552: 126-131, 2017.
17. Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, *et al*: The N⁶-methyladenosine (m⁶A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. *Nat Med* 23: 1369-1376, 2017.
18. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E and Semenza GL: Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. *Oncotarget* 7: 64527-64542, 2016.
19. Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W and Ye L: HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. *Cancer Lett* 415: 11-19, 2018.
20. Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, Doki Y, Mori M, Ishii H and Ogawa K: The epitranscriptome m⁶A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. *Int J Oncol* 52: 621-629, 2018.
21. Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C, Wei M and Liu L: 1981O-The m(6)A methyltransferase METTL3 promotes gastric cancer progression through facilitating primary microRNA maturation. *Ann Oncol* 30: v797, 2019.
22. Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, Zhang M, Chen X, Pan T, Yan L, *et al*: The mechanism of m⁶A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β -elemene. *Cell Death Dis* 11: 969, 2020.

23. Li X, Tang J, Huang W, Wang F, Li P, Qin C, Qin Z, Zou Q, Wei J, Hua L, *et al*: The M6A methyltransferase METTL3: Acting as a tumor suppressor in renal cell carcinoma. *Oncotarget* 8: 96103-96116, 2017.
24. Robinson M, Shah P, Cui YH and He YY: The role of dynamic m⁶A RNA methylation in photobiology. *Photochem Photobiol* 95: 95-104, 2019.
25. Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, Li L, Chen R, Wang Y, Deng R, *et al*: SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. *Nucleic Acids Res* 46: 5195-5208, 2018.
26. Selberg S, Blokhina D, Aatonen M, Koivisto P, Siltanen A, Mervaala E, Kankuri E and Karelson M: Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site. *Cell Rep* 26: 3762-3771.e5, 2019.
27. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QQ, Zhou WP and Sun SH: METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N⁶-methyladenosine-dependent primary MicroRNA processing. *Hepatology* 65: 529-543, 2017.
28. Ruzkowska A: METTL16, methyltransferase-like protein 16: Current insights into structure and function. *Int J Mol Scis* 22: 2176, 2021.
29. Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, Hübner C, Sloan KE and Bohnsack MT: Human METTL16 is a N⁶-methyladenosine (m⁶A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. *EMBO Rep* 18: 2004-2014, 2017.
30. Detich N, Hamm S, Just G, Knox JD and Szyf M: The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: A candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. *J Biol Chem* 278: 20812-20820, 2003.
31. Shima H, Matsumoto M, Ishigami Y, Ebina M, Muto A, Sato Y, Kumagai S, Ochiai K, Suzuki T and Igarashi K: S-Adenosylmethionine synthesis is regulated by selective N⁶-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. *Cell Rep* 21: 3354-3363, 2017.
32. Schwartz S, Mumbach MR, Jovanovic M, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N, *et al*: Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep* 8: 284-296, 2014.
33. Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, *et al*: Mammalian WTAP is a regulatory subunit of the RNA N⁶-methyladenosine methyltransferase. *Cell Res* 24: 177-189, 2014.
34. Sorci M, Ianniello Z, Cruciani S, Larivera S, Ginistrelli LC, Capuano E, Marchioni M, Fazi F and Fatica A: METTL3 regulates WTAP protein homeostasis. *Cell Death Dis* 9: 796, 2018.
35. Xi Z, Xue Y, Zheng J, Liu X, Ma J and Liu Y: WTAP expression predicts poor prognosis in malignant glioma patients. *J Mol Neurosci* 60: 131-136, 2016.
36. Li BQ, Huang S, Shao QQ, Sun J, Zhou L, You L, Zhang TP, Liao Q, Guo JC and Zhao YP: WTI-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. *Oncol Lett* 13: 2531-2538, 2017.
37. Tang J, Wang F, Cheng G, Si S, Sun X, Han J, Yu H, Zhang W, Lv Q, Wei JF and Yang H: Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. *J Exp Clin Cancer Res* 37: 40, 2018.
38. Su R, Li Z, Weng H, Weng X and Chen J: FTO Plays an oncogenic role in acute myeloid leukemia as a N⁶-methyladenosine RNA demethylase. *Blood* 128: 2706-2706, 2016.
39. Chao Y, Shang J and Ji W: ALKBH5-m⁶A-FOXO1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. *Biochem Biophys Res Commun* 521: 499-506, 2020.
40. Kusinska R, Górniak P, Pastorczak A, Fendler W, Potemski P, Mlynarski W and Kordek R: Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast cancer risk. *Mol Biol Rep* 39: 2915-2919, 2012.
41. Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, *et al*: RNA N⁶-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. *Mol Cancer* 18: 46, 2019.
42. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG and He C: N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol* 7: 885-887, 2011.
43. Tian R, Zhang S, Sun D, Bei C, Li D, Zheng C, Song X, Chen M, Tan S, Zhu X and Zhang H: M6A demethylase FTO plays a tumor suppressor role in thyroid cancer. *DNA Cell Biol* 39: 2184-2193, 2020.
44. Gaudet MM, Yang HP, Bosquet JG, Healey CS, Ahmed S, Dunning AM, Easton DF, Spurdle AB, Ferguson K, O'Mara T, *et al*: No association between FTO or HHEX and endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev* 19: 2106-2109, 2010.
45. Li Y, Zheng D, Wang F, Xu Y, Yu H and Zhang H: Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric cancer. *Dig Dis Sci* 64: 1503-1513, 2019.
46. Tsuruta N, Tsuchihashi K, Ohmura H, Yamaguchi K, Ito M, Ariyama H, Kusaba H, Akashi K and Baba E: RNA N⁶-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells. *Biochem Biophys Res Commun* 530: 235-239, 2020.
47. Hernández-Caballero ME and Sierra-Ramírez JA: Single nucleotide polymorphisms of the FTO gene and cancer risk: An overview. *Mol Biol Rep* 42: 699-704, 2015.
48. Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, *et al*: FTO plays an oncogenic role in acute myeloid leukemia as a N⁶-methyladenosine RNA demethylase. *Cancer Cell* 31: 127-141, 2017.
49. Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY and Zhe H: FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. *Mol Carcinog* 57: 590-597, 2018.
50. Xu C, Liu K, Tempel W, Demetriades M, Aik W, Schofield CJ and Min J: Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N⁶-methyladenosine RNA demethylation. *J Biol Chem* 289: 17299-17311, 2014.
51. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X and Semenza GL: Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. *Proc Natl Acad Sci USA* 113: E2047-E2056, 2016.
52. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bögl O, *et al*: m⁶A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. *Cancer Cell* 31: 591-606.e6, 2017.
53. He Y, Hu H, Wang Y, Yuan H, Lu Z, Wu P, Liu D, Tian L, Yin J, Jiang K and Miao Y: ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCNK15-AS1 methylation. *Cell Physiol Biochem* 48: 838-846, 2018.
54. Lee Y, Choe J, Park OH and Kim YK: Molecular mechanisms driving mRNA degradation by m6A modification. *Trends Genet* 36: 177-188, 2020.
55. Sheng H, Li Z, Su S, Sun W, Zhang X, Li L, Li J, Liu S, Lu B, Zhang S and Shan C: YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. *Carcinogenesis* 41: 541-550, 2020.
56. Li Z, Zhang Y, Ramanujan K, Ma Y, Kirsch DG and Glass DJ: Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMG2-IGF2BP2 pathway. *Cancer Res* 73: 3041-3050, 2013.
57. Liao S, Sun H and Xu C: YTH domain: A family of N⁶-methyladenosine (m⁶A) readers. *Genomics Proteomics Bioinformatics* 16: 99-107, 2018.
58. Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY, *et al*: Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. *Mol Cell* 61: 507-519, 2016.
59. Li J, Meng S, Xu M, Wang S, He L, Xu X, Wang X and Xie L: Downregulation of N⁶-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N⁶-methyladenosine levels. *Oncotarget* 9: 3752-3764, 2017.
60. Bhardwaj U, Powell P and Goss DJ: Eukaryotic initiation factor (eIF3) mediates barley yellow dwarf viral mRNA 3'-5'UTR interactions and 40S ribosomal subunit binding to facilitate cap-independent translation. *Nucleic Acids Res* 47: 6225-6235, 2019.
61. Li Z, Lin S, Jiang T, Wang J, Lu H, Tang H, Teng M and Fan J: Overexpression of eIF3e is correlated with colon tumor development and poor prognosis. *Int J Clin Exp Pathol* 7: 6462-6474, 2014.
62. Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, *et al*: mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. *Nature* 561: 556-560, 2018.

63. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, *et al.*: Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. *Nature* 485: 201-206, 2012.
64. Antanaviciute A, Baquero-Perez B, Watson CM, Harrison SM, Lascelles C, Crinnion L, Markham AF, Bonthron DT, Whitehouse A and Carr IM: m⁶aViewer: Software for the detection, analysis, and visualization of N⁶-methyladenosine peaks from m⁶A-seq/ME-RIP sequencing data. *RNA* 23: 1493-1501, 2017.
65. Zhang SY, Zhang SW, Fan XN, Zhang T, Meng J and Huang Y: FunDMDeep-m⁶A: Identification and prioritization of functional differential m⁶A methylation genes. *Bioinformatics* 35: i90-i98, 2019.
66. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3'UTRs and near stop codons. *Cell* 149: 1635-1646, 2012.
67. Chandola U, Das R and Panda B: Role of the N⁶-methyladenosine RNA mark in gene regulation and its implications on development and disease. *Brief Funct Genomics* 14: 169-179, 2015.
68. Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C and Chen Y: The role of m⁶A modification in the biological functions and diseases. *Signal Transduct Target Ther* 6: 74, 2021.
69. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE and Jaffrey SR: Single-nucleotide-resolution mapping of m⁶A and m⁶Am throughout the transcriptome. *Nat Methods* 12: 767-772, 2015.
70. Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, Linder B, Pickering BF, Vasseur JJ, Chen Q, *et al.*: Reversible methylation of m⁶A_m in the 5'cap controls mRNA stability. *Nature* 541: 371-375, 2017.
71. Chen K, Lu Z, Wang X, Fu Y, Luo GZ, Liu N, Han D, Dominissini D, Dai Q, Pan T, *et al.*: High-resolution N(6)-methyladenosine (m(6)A) map using photo-crosslinking-assisted m(6)A sequencing. *Angew Chem Int Ed Engl* 54: 1587-1590, 2015.
72. Ke S, Alemu EA, Mertens C, Gantman EC, Fak JJ, Mele A, Haripal B, Zucker-Scharff I, Moore MJ, Park CY, *et al.*: A majority of m⁶A residues are in the last exons, allowing the potential for 3'UTR regulation. *Genes Dev* 29: 2037-2053, 2015.
73. Molinie B, Wang J, Lim KS, Hillebrand R, Lu ZX, Van Wittenberghe N, Howard BD, Daneshvar K, Mullen AC, Dedon P, *et al.*: m(6)A-LAIC-seq reveals the census and complexity of the m(6)A epitranscriptome. *Nat Methods* 13: 692-698, 2016.
74. Liu N, Parisien M, Dai Q, Zheng G, He C and Pan T: Probing N⁶-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. *RNA* 19: 1848-1856, 2013.
75. Li X, Zhu P, Ma S, Song J, Bai J, Sun F and Yi C: Chemical pulldown reveals dynamic pseudouridylation of the mammalian transcriptome. *Nat Chem Biol* 11: 592-597, 2015.
76. Golovina AY, Dzama MM, Petriukov KS, Zatspepin TS, Sergiev PV, Bogdanov AA and Dontsova OA: Method for site-specific detection of m⁶A nucleoside presence in RNA based on high-resolution melting (HRM) analysis. *Nucleic Acids Res* 42: e27, 2014.
77. Wang M, Liu J, Zhao Y, He R, Xu X, Guo X, Li X, Xu S, Miao J, Guo J, *et al.*: Upregulation of METTL14 mediates the elevation of PERP mRNA N⁶ adenosine methylation promoting the growth and metastasis of pancreatic cancer. *Mol Cancer* 19: 130, 2020.
78. Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J and Peng J: m⁶A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. *J Cell Physiol* 236: 2649-2658, 2021.
79. Wang Y, Wang H, Xi F, Wang H, Han X, Wei W, Zhang H, Zhang Q, Zheng Y, Zhu Q, *et al.*: Profiling of circular RNA N⁶-methyladenosine in moso bamboo (*Phyllostachys edulis*) using nanopore-based direct RNA sequencing. *J Integr Plant Biol* 62: 1823-1838, 2020.
80. Zhang Z, Wang Q, Zhang M, Zhang W, Zhao L, Yang C, Wang B, Jiang K, Ye Y, Shen Z and Wang S: Comprehensive analysis of the transcriptome-wide m⁶A methylome in colorectal cancer by MeRIP sequencing. *Epigenetics* 16: 425-435, 2021.
81. Han Z, Yang B, Wang Q, Hu Y, Wu Y and Tian Z: Comprehensive analysis of the transcriptome-wide m⁶A methylome in invasive malignant pleomorphic adenoma. *Cancer Cell Int* 21: 142, 2021.
82. Zhang YC, Zhang SW, Liu L, Liu H, Zhang L, Cui X, Huang Y and Meng J: Spatially enhanced differential RNA methylation analysis from affinity-based sequencing data with hidden Markov model. *Biomed Res Int* 2015: 852070, 2015.
83. Li GQ, Liu Z, Shen HB and Yu DJ: TargetM6A: Identifying N⁶-Methyladenosine sites from RNA sequences via position-specific nucleotide propensities and a support vector machine. *IEEE Trans Nanobioscience* 15: 674-682, 2016.
84. Chen W, Feng P, Ding H, Lin H and Chou KC: iRNA-Methyl: Identifying N(6)-methyladenosine sites using pseudo nucleotide composition. *Anal Biochem* 490: 26-33, 2015.
85. Jia CZ, Zhang JJ and Gu WZ: RNA-MethylPred: A high-accuracy predictor to identify N(6)-methyladenosine in RNA. *Anal Biochem* 510: 72-75, 2016.
86. Zhou Y, Zeng P, Li YH, Zhang Z and Cui Q: SRAMP: Prediction of mammalian N⁶-methyladenosine (m⁶A) sites based on sequence-derived features. *Nucleic Acids Res* 44: e91, 2016.
87. Woosley AN, Dalton AC, Hussey GS, Howley BV, Mohanty BK, Grelet S, Dincman T, Bloos S, Olsen SK and Howe PH: TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis. *Oncogene* 38: 3794-3811, 2019.
88. Song T, Yang Y, Wei H, Xie X, Lu J, Zeng Q, Peng J, Zhou Y, Jiang S and Peng J: Zfp217 mediates m⁶A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation. *Nucleic Acids Res* 47: 6130-6144, 2019.
89. Zhao X and Cui L: Development and validation of a m⁶A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma. *Am J Cancer Res* 9: 2156-2169, 2019.
90. Du S, Hu W, Zhao YI, Zhou H, Wen W, Xu M, Zhao P and Liu K: Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. *Cancer Biomark* 24: 269-277, 2019.
91. Ercolani C, Di Benedetto A, Terrenato I, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Buglioni S, Ramieri MT, Mentuccia L, *et al.*: Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. *Cancer Biol Ther* 18: 339-346, 2017.
92. Ni TK and Kuperwasser C: Abstract 4995: Premature polyadenylation causes oncogenic truncations of the tumor suppressor genes BRCA1, LATS1 and MAGI3 in breast cancer. *Cancer Res* 77: 4995, 2017.
93. Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J, Torigoe T, Maeda H, Kutomi G, Okita K, *et al.*: RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. *Cancer Lett* 376: 34-42, 2016.
94. Zhao YL, Liu YH, Wu RF, Bi Z, Yao YX, Liu Q, Wang YZ and Wang XX: Understanding m⁶A function through uncovering the diversity roles of YTH domain-containing proteins. *Mol Biotechnol* 61: 355-364, 2019.
95. Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z, Hu B, Zhou J, Zhao Z, Feng M, *et al.*: YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. *Mol Cancer* 18: 163, 2019.
96. Zhao M, Jia M, Xiang Y, Zeng Y, Yu W, Xiao B and Dai R: METTL3 promotes the progression of hepatocellular carcinoma through m⁶A-mediated up-regulation of microRNA-873-5p. *Am J Physiol Gastrointest Liver Physiol*: Jul 20, 2020 (Epub ahead of print). doi: 10.1152/ajpgi.00161.2020.
97. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QG, Zhou WP and Sun SH: METTL14 suppresses the metastatic potential of HCC by modulating m⁶A-dependent primary miRNA processing. *Hepatology* 65: 529-543, 2017.
98. Xu XD: Effects of N6-methylpurine(m6A) methyltransferase METTL14 on the proliferation, invasion and metastasis of pancreatic cancer and its mechanism. *Huazhong Univ Sci Technol*, (PhD Thesis), 2017.
99. Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, *et al.*: m⁶A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. *Nat Cell Biol* 20: 1074-1083, 2018.
100. Wang X, Li Z, Kong B, Song C, Cong J, Hou J and Wang S: Reduced m⁶A mRNA methylation is correlated with the progression of human cervical cancer. *Oncotarget* 8: 98918-98930, 2017.
101. Ma X, Li Y, Wen J and Zhao Y: m⁶A RNA methylation regulators contribute to malignant development and have a clinical prognostic effect on cervical cancer. *Am J Transl Res* 12: 8137-8146, 2020.
102. Ji F, Lu Y, Chen S, Yu Y, Lin X, Zhu Y and Luo X: IGF2BP2-modified circular RNA circARHGAP12 promotes cervical cancer progression by interacting m6A/FOXMI manner. *Cell Death Discov* 7: 215, 2021.

103. Lin X, Chai G, Wu Y, Chen F, Liu J, Luo G, Tauler J, Du J, Lin S, He C and Wang H: RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. *Nat Commun* 10: 2065, 2019.
104. Huang GZ, Wu QQ, Zheng ZN, Shao TR, Chen YC, Zeng WS and Lv XZ: M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT. *Aging (Albany NY)* 12: 11667-11684, 2020.
105. Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z and Zhao G: METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. *Mol Cancer* 18: 142, 2019.
106. Li H, Su Q, Li B, Lan L, Wang C, Li W, Wang G, Chen W, He Y and Zhang C: High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration. *J Cell Mol Med* 24: 4452-4465, 2020.
107. Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C, Wei M, Liu T, Li L and Liu L: N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. *Cell Death Dis* 11: 836, 2020.
108. Lin S, Liu J, Jiang W, Wang P, Sun C, Wang X, Chen Y and Wang H: METTL3 promotes the proliferation and mobility of gastric cancer cells. *Open Med (Wars)* 14: 25-31, 2019.
109. Liu T, Yang S, Sui J, Xu SY, Cheng YP, Shen B, Zhang Y, Zhang XM, Yin LH, Pu YP and Liang GY: Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer. *J Cell Physiol* 235: 548-562, 2020.
110. Du C, Lv C, Feng Y and Yu S: Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. *J Exp Clin Cancer Res* 39: 223, 2020.
111. Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, *et al*: The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. *Nucleic Acids Res* 48: 3816-3831, 2020.
112. Huang H, Weng H and Chen J: m(6)A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. *Cancer Cell* 37: 270-288, 2020.
113. Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, Yuan W, Kan Q and Sun Z: The interplay between m6A RNA methylation and noncoding RNA in cancer. *J Hematol Oncol* 12: 121, 2019.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.